Table 1.
Comparison of baseline characteristics between the BKVAN and control groups in kidney transplantation
| Variable | BKVAN group (n = 15) | Control group (n = 356) | P value |
|---|---|---|---|
| Recipient age (yr) | 47.9 ± 9.1 | 42.4 ± 11.7 | 0.074 |
| Recipient male gender | 13 (86.7) | 198 (55.6) | 0.017 |
| Donor age (yr) | 46.8 ± 5.6 | 39.7 ± 13.1 | < 0.001 |
| Donor male gender | 6 (40.0) | 205 (57.6) | 0.287 |
| Donor type | 0.179 | ||
| Living: deceased | 6 (40):9 (60) | 213 (59.8):143 (40.2) | |
| KT number | 1.000 | ||
| First: Second | 14 (93.3):1 (6.7) | 309 (86.8):47 (13.2) | |
| Dialysis type before KT | 0.336 | ||
| Hemodialysis: Peritoneal dialysis | 11 (73.3):4 (26.7) | 259 (72.8):59 (16.6) | |
| Cause of end-stage renal disease | 0.385 | ||
| Glomerulonephritis | 11 (73.3) | 268 (75.3) | |
| Diabetes mellitus | 1 (6.7) | 50 (14.0) | |
| Hypertension | 1 (6.7) | 15 (4.2) | |
| ADPKD | 1 (6.7) | 11 (3.1) | |
| Others | 1 (6.7) | 12 (3.4) | |
| HLA mismatch number | 4.3 ± 1.7 | 3.3 ± 1.6 | 0.053 |
| Induction immunosuppressant | < 0.001 | ||
| Basiliximab | 10 (66.7) | 240 (67.4) | |
| Antithymocyte globulin | 2 (13.3) | 15 (4.2) | |
| None | 3 (20) | 101 (28.4) | |
| Main immunosuppressant | 0.611 | ||
| Tacrolimus | 15 (100) | 332 (93.3) | |
| Cyclosporine | 0 | 24 (6.7) |
Data are expressed as the mean ± standard deviation or number (%).
ADPKD, autosomal dominant polycystic kidney disease; BKVAN, BK virus-associated nephropathy; HLA, human leukocyte antigen; KT, kidney transplantation.